Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke.

Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM; TNK in Stroke Investigators.

Stroke. 2005 Mar;36(3):607-12. Epub 2005 Feb 3.

2.

Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.

Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, Subramaniam S, Goyal M, Patil S, Menon BK, Barber PA, Dowlatshahi D, Field T, Asdaghi N, Camden MC, Hill MD; TEMPO-1 Investigators.

Stroke. 2015 Mar;46(3):769-74. doi: 10.1161/STROKEAHA.114.008504. Epub 2015 Feb 12.

4.

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.

Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B; Tenecteplase in Stroke Investigators.

Stroke. 2010 Apr;41(4):707-11. doi: 10.1161/STROKEAHA.109.572040. Epub 2010 Feb 25.

5.

The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results.

Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D.

Stroke. 2006 Aug;37(8):2100-6. Epub 2006 Jun 29.

6.

Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage.

Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurrú C, Biller J.

Stroke. 2001 Jan;32(1):12-6.

7.

Argatroban tPA stroke study: study design and results in the first treated cohort.

Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, Mikulik R, Garami Z, Shaw SG, Matherne DE, Moyé LA, Alexandrov AV, Grotta JC.

Arch Neurol. 2006 Aug;63(8):1057-62.

PMID:
16908730
8.

Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes.

Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, et al.

Stroke. 1992 May;23(5):632-40.

9.

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.

Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang-Clow F, Fox NL, Braunwald E.

Am Heart J. 1999 May;137(5):786-91.

PMID:
10220625
10.

Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations.

Seitz RJ, Hamzavi M, Junghans U, Ringleb PA, Schranz C, Siebler M.

Stroke. 2003 Aug;34(8):1932-5. Epub 2003 Jun 26.

11.

Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation.

Zhang JB, Ding ZY, Yang Y, Sun W, Hai F, Sui XN, Li XY, Wang HZ, Wang XT, Zheng JL.

Neurol Res. 2010 May;32(4):353-8. doi: 10.1179/016164110X12656393665206.

PMID:
20483000
12.

Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.

Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR.

Stroke. 1992 May;23(5):641-5.

13.

The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis.

Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD.

Stroke. 2006 Aug;37(8):2107-14. Epub 2006 Jun 29.

14.

TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.

Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E.

Circulation. 1997 Jan 21;95(2):351-6.

15.

Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.

Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T.

Stroke. 1999 Dec;30(12):2598-605.

16.

Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke.

Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D, Kanter D, Jauch E, Carrozzella J, Spilker J, Broderick J.

Stroke. 2000 Nov;31(11):2552-7.

17.

Intra-arterial tenecteplase for treatment of acute ischemic stroke: feasibility and comparative outcomes.

Georgiadis AL, Memon MZ, Shah QA, Vazquez G, Tariq NA, Suri MF, Taylor RA, Qureshi AI.

J Neuroimaging. 2012 Jul;22(3):249-54. doi: 10.1111/j.1552-6569.2011.00628.x. Epub 2011 Aug 29.

PMID:
21883621
18.

Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.

Giugliano RP, Roe MT, Harrington RA, Gibson CM, Zeymer U, Van de Werf F, Baran KW, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH, Braunwald E, Califf RM; INTEGRITI Investigators.

J Am Coll Cardiol. 2003 Apr 16;41(8):1251-60.

19.

Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model.

Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J.

Stroke. 2001 Mar;32(3):748-52.

20.

Intravenous thrombolysis for acute ischemic stroke occurring during hospitalization for transient ischemic attack.

Tsivgoulis G, Sharma VK, Mikulik R, Krogias C, Haršány M, Bavarsad Shahripour R, Athanasiadis D, Teoh HL, Piperidou C, Alexandrov AV.

Int J Stroke. 2014 Jun;9(4):413-8. doi: 10.1111/ijs.12125. Epub 2013 Aug 26.

PMID:
23981541

Supplemental Content

Support Center